Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. European Lung Cancer Congress 2023

Is neoadjuvant chemo-immunotherapy superior to adjuvant immunotherapy?

Second vote and conclusions

Date

30 Mar 2023

Session

Is neoadjuvant chemo-immunotherapy superior to adjuvant immunotherapy?

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Lizza Hendriks

Authors

L. Hendriks

Author affiliations

  • Maastricht University Medical Center (MUMC), Maastricht/NL

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Introduction and first vote

Presenter: Lizza Hendriks

Session: Is neoadjuvant chemo-immunotherapy superior to adjuvant immunotherapy?

Resources:

Slides

Webcast

Yes

Presenter: Egbert Smit

Session: Is neoadjuvant chemo-immunotherapy superior to adjuvant immunotherapy?

Resources:

Slides

Webcast

No

Presenter: Heather Wakelee

Session: Is neoadjuvant chemo-immunotherapy superior to adjuvant immunotherapy?

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.